901 related articles for article (PubMed ID: 29400475)
1. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
3. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
4. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
Molecules; 2020 May; 25(11):. PubMed ID: 32486054
[TBL] [Abstract][Full Text] [Related]
7. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Investigations to Explore the Difference between the Diastereomers [
Borgna F; Deberle LM; Busslinger SD; Tschan VJ; Walde LM; Becker AE; Schibli R; Müller C
Mol Pharm; 2022 Jul; 19(7):2105-2114. PubMed ID: 35544699
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of a New Series of Albumin-Binding
Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
[TBL] [Abstract][Full Text] [Related]
10.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
11. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
12. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands.
Tschan VJ; Borgna F; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):470-480. PubMed ID: 34402925
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
[TBL] [Abstract][Full Text] [Related]
14. Development of [
Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
[TBL] [Abstract][Full Text] [Related]
15. Combined Application of Albumin-Binding [
Borgna F; Deberle LM; Cohrs S; Schibli R; Müller C
Mol Pharm; 2020 Jun; 17(6):2044-2053. PubMed ID: 32383887
[TBL] [Abstract][Full Text] [Related]
16. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
18. Development of
Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
[TBL] [Abstract][Full Text] [Related]
19. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
Śmiłowicz D; Schlyer D; Boros E; Meimetis L
Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
